Wells Fargo’s Sage Therapeutics SAGE Stock Holding History

Wells Fargo’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-800	Closed	-$60K	–	7353
2021 Q1	$60K	Buy	+800	New	+$65.6K	﹤0.01%	5733
2020 Q4	–	Sell	-60,000	Closed	-$579K	–	6937
2020 Q3	$579K	Buy	+60,000	New	+$3.04M	﹤0.01%	4239
2020 Q1	–	Sell	-5,000	Closed	-$42K	–	6707
2019 Q4	$42K	Buy	+5,000	New	+$615K	﹤0.01%	5564
2019 Q3	–	Sell	-4,200	Closed	-$31K	–	6658
2019 Q2	$31K	Buy	+4,200	New	+$717K	﹤0.01%	5690
2018 Q2	–	Sell	-9,200	Closed	-$21K	–	6529
2018 Q1	$21K	Buy	+9,200	New	+$1.56M	﹤0.01%	5800

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Wells Fargo's SAGE Position: Q3 2025 in Review

Wells Fargo sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 37,033 shares — an estimated $338K sold.

Wells Fargo first reported a position in SAGE in Q4 2014 and held it in 43 quarters. The position peaked at $71.8M in Q2 2019. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Wells Fargo reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Wells Fargo sold 37,033 Sage Therapeutics shares in Q3 2025, an estimated $338K.
Wells Fargo first reported a position in Sage Therapeutics in Q4 2014 and held it in 43 quarters.
Wells Fargo's Sage Therapeutics position peaked at $71.8M in Q2 2019.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.